InVivoMAb anti-human PD-1 (CD279)

Tkachev V, Goodell S, Opipari AW, et al. Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol. 2015,194(12):5789-800. doi: 10.4049/jimmunol.1402180

Tsukahara T, Iwase N, Kawakami K, et al. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies. Gene Ther. 2015,22(2):209-15. doi: 10.1038/gt.2014.104

Wang C, Yi T, Qin L, et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J Clin Invest. 2013,123(4):1677-93. doi: 10.1172/JCI66204

Singh A, Dey AB, Mohan A, et al. Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-γ producing T cells. PLoS One. 2012,7(9):e44728. doi: 10.1371/journal.pone.0044728

Rosignoli G, Lim CH, Bower M, et al. Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clin Exp Immunol. 2009,157(1):90-7. doi: 10.1111/j.1365-2249.2009.03960.x

Jurado JO, Alvarez IB, Pasquinelli V, et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol. 2008,181(1):116-25.